Pfizer’s RSV Vaccine Can Help Protect Older Adults From Severe Disease

In May, the FDA approved Pfizer’s respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. The approval of Abrysvo was a significant step for alleviating the public health burden and treating the disease in high-risk populations. RSV can cause severe disease in older adults and leads to nearly 14,000 deaths among those 65 and older each year in the United States, which is why the development of a vaccine was of critical importance.

At the National Community Pharmacists Association (NCPA) 2023 Convention and Expo, Stephen L. Foster, PharmD, FAPhA, FNAP, former liaison representative on the Advisory Committee on Immunization Practices (ACIP) for the American Pharmacists Association (APhA), discussed the prevalence of RSV and how Abrysvo can help protect the older adult population.